Biomimetic Multimodal Evaluation Reveals Enhanced Efficacy and Safety of Cyclosporine A Nanomicelles (CycloNex) for Advanced Dry Eye Management
Small · 2026-11 · 22 (63)
DOI: 10.1002/smll.74981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 02.08.2026. Verfasst von Xing Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, People's Republic of China. Hauptthemen laut MEDLINE: Cyclosporine, Micelles, Dry Eye Syndromes, Biomimetics. Die Arbeit nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hebei Province Funding Project for Introduced Overseas Personnel, Hebei Province Central Guidance Local Science and Technology Development Funding Project.
Abstract (Originalsprache)
Dry eye disease (DED), which affects over 30% of the global population, demands advanced therapeutic strategies to overcome ocular bioavailability challenges. We developed nanomicelles (RH40‐P188/RH40‐P407, CycloNex) for enhanced cyclosporine A (CsA) delivery through innovative biological validation platforms. The 15‐nm micelles demonstrated exceptional stability (3 months at 25°C) and deep tissue penetration (50 µm in 3D corneal spheroids), outperforming Cequa by 2.3‐fold in ex vivo rabbit corneal accumulation. A breakthrough microfluidic‐integrated 3D total corneal model revealed 82% prolonged ocular retention vs. Cequa, while our hyperosmotic cell platform showed 55% greater reactive oxygen species reduction and 44% lower TNF‐α expression. In vivo studies confirmed NM P188 ‐CsA's superior bioavailability, and corneal repair was completed within 14 days in mice with benzalkonium chloride‐induced dry eye. These findings, validated through six complementary biological models—including HET‐CAM irritation scoring (0.89 vs. Cequa's 1.34)—establish a new paradigm for ocular nanotherapeutic evaluation while demonstrating clinically translatable advantages over current standards.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang, People's Republic of China.
- Department of Ophthalmology, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
- State Key Laboratory of New Pharmaceutical Preparations and Excipients, Hebei Medical University, Shijiazhuang, People's Republic of China.
Förderung
- National Natural Science Foundation of China
- Hebei Province Funding Project for Introduced Overseas Personnel
- Hebei Province Central Guidance Local Science and Technology Development Funding Project
- Shijiazhuang Basic Research Project
Zitieren
APA
Dong, X., Cong, K., Lu, Y., Yang, S., Sun, Y., Hao, J., Liu, Y., Zhang, Y., Liu, C., He, C., Hao, Y., & Xiang, B. (2026). Biomimetic Multimodal Evaluation Reveals Enhanced Efficacy and Safety of Cyclosporine A Nanomicelles (CycloNex) for Advanced Dry Eye Management. Small, 22(63). https://doi.org/10.1002/smll.74981
Vancouver
Dong X, Cong K, Lu Y, Yang S, Sun Y, Hao J, et al. Biomimetic Multimodal Evaluation Reveals Enhanced Efficacy and Safety of Cyclosporine A Nanomicelles (CycloNex) for Advanced Dry Eye Management. Small. 2026;22(63). doi:10.1002/smll.74981
BibTeX
@article{Dong2026,
author = {Dong, Xing and Cong, Kexin and Lu, Yu and Yang, Shaokun and Sun, Yanan and Hao, Jintao and Liu, Yixuan and Zhang, Yaxin and Liu, Chun and He, Chaoxing and Hao, Yuhua and Xiang, Bai},
title = {Biomimetic Multimodal Evaluation Reveals Enhanced Efficacy and Safety of Cyclosporine A Nanomicelles (CycloNex) for Advanced Dry Eye Management},
journal = {Small},
year = {2026},
volume = {22},
number = {63},
doi = {10.1002/smll.74981}
}
EUVIMED